Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Cancelled Post Market
Current status date:
2011-07-27
Original market date: See footnote 1
1998-02-19
Product name:
HYPAQUE ORAL POWDER
DIN:
02180685
Product Monograph/Veterinary Labelling:
Date:
2006-03-20
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
GE HEALTHCARE CANADA INC
1919 Minnesota Court
Mississauga
Ontario
Canada
L5N 0C9
Class:
Human
Dosage form(s):
Powder
Route(s) of administration:
Oral , Rectal
Number of active ingredient(s):
1
Schedule(s):
Ethical
American Hospital Formulary Service (AHFS): See footnote 3
36:68.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
V08AA01 DIATRIZOIC ACID
Active ingredient group (AIG) number:See footnote5
0101806002
| Active ingredient(s) | Strength |
|---|---|
| DIATRIZOATE SODIUM | 997.4 MG / G |